ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ME 23andMe Holding Company

0.56
-0.0268 (-4.57%)
May 20 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,486,738
Bid Price 0.5506
Ask Price 0.56
News -
Day High 0.6052

Low
0.35

52 Week Range

High
2.20

Day Low 0.54
Company Name Stock Ticker Symbol Market Type
23andMe Holding Company ME NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0268 -4.57% 0.56 19:58:48
Open Price Low Price High Price Close Price Prev Close
0.59 0.54 0.6052 0.5466 0.5868
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,784 2,486,738 $ 0.5759505 $ 1,432,238 - 0.35 - 2.20
Last Trade Time Type Quantity Stock Price Currency
19:58:48 formt 100 $ 0.56 USD

23andMe Holding Company Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
265.6M 482.92M - 299.49M -311.66M -0.65 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

23andMe News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ME Message Board. Create One! See More Posts on ME Message Board See More Message Board Posts

Historical ME Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.500.6380.500.58317513,835,1730.0612.00%
1 Month0.4920.6380.44440.51517033,478,4270.06813.82%
3 Months0.57840.68710.350.50285416,027,567-0.0184-3.18%
6 Months0.85631.020.350.65168096,158,893-0.2963-34.60%
1 Year1.932.200.350.86518974,567,468-1.37-70.98%
3 Years11.0013.680.352.973,453,149-10.44-94.91%
5 Years11.0013.680.352.973,453,149-10.44-94.91%

23andMe Description

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.

Your Recent History

Delayed Upgrade Clock